KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Net Income towards Common Stockholders: 2009-2025

Historic Net Income towards Common Stockholders for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to $1.1 billion.

  • Vertex Pharmaceuticals' Net Income towards Common Stockholders rose 3.59% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year increase of 865.96%. This contributed to the annual value of -$535.6 million for FY2024, which is 114.80% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at $1.1 billion for Q3 2025, which was up 4.84% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of $1.1 billion in Q1 2024 and a low of -$3.6 billion during Q2 2024.
  • Its 3-year average for Net Income towards Common Stockholders is $531.5 million, with a median of $968.8 million in 2023.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first soared by 1,109.70% in 2022, then crashed by 492.44% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at $770.1 million in 2021, then climbed by 6.34% to $818.9 million in 2022, then increased by 18.31% to $968.8 million in 2023, then declined by 5.76% to $913.0 million in 2024, then increased by 3.59% to $1.1 billion in 2025.
  • Its Net Income towards Common Stockholders was $1.1 billion in Q3 2025, compared to $1.0 billion in Q2 2025 and $646.3 million in Q1 2025.